United States - English - NLM (National Library of Medicine)

nelco laboratories, inc. - aspergillus fumigatus (unii: x88df51t48) (aspergillus fumigatus - unii:x88df51t48) - allergenic extracts are indicated for use in diagnostic testing and as part of a treatment regime for allergic disease, as established by allergy history and skin test reactivity. allergenic extracts are indicated for the treatment of allergen specific allergic disease for use as hyposensitization or immunotherapy when avoidance of specific allergens can not be attained. the use of allergenic extracts for therapeutic purpose has been established by well-controlled clinical studies. allergenic extracts may be used as adjunctive therapy along with pharmacotherapy which includes antihistamines, corticosteroids, and cromoglycate, and avoidance measures. allergenic extracts for therapeutic use should be given using only the allergen selection to which the patient is allergic, has a history of exposure and are likely to be exposed to again. allergenic extracts should not be used if the patient has asthma, cardiovascular disease, emphysema, diabetes, bleeding diathesis or pregnancy, unless a specific diagnosis of t

United States - English - NLM (National Library of Medicine)

nelco laboratories, inc. - aspergillus fumigatus (unii: x88df51t48) (aspergillus fumigatus - unii:x88df51t48) - allergenic extracts are indicated for use in diagnostic testing and as part of a treatment regime for allergic disease, as established by allergy history and skin test reactivity. allergenic extracts are indicated for the treatment of allergen specific allergic disease for use as hyposensitization or immunotherapy when avoidance of specific allergens can not be attained. the use of allergenic extracts for therapeutic purpose has been established by well-controlled clinical studies. allergenic extracts may be used as adjunctive therapy along with pharmacotherapy which includes antihistamines, corticosteroids, and cromoglycate, and avoidance measures. allergenic extracts for therapeutic use should be given using only the allergen selection to which the patient is allergic, has a history of exposure and are likely to be exposed to again. allergenic extracts should not be used if the patient has asthma, cardiovascular disease, emphysema, diabetes, bleeding diathesis or pregnancy, unless a specific diagnosis of t

United Arab Emirates - English - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

ibn batuta medicine & medical equipment store llc sharjah-ibrahim mohammed al madfa street - aspergillus oryzae, ananas comosus, carica papaya - tablet - combination - gastrointestinal system-natural source - see indication field for description, herbal remedy-n/a

New Zealand - English - Medsafe (Medicines Safety Authority)

ebos group ltd - allergen extracts 100 pnu/ml (alternaria, aspergillus, cladosporium, penicillium); allergen extracts 1000 pnu/ml (alternaria, aspergillus, cladosporium, penicillum,); allergen extracts 10000 pnu/ml (alternaria, aspergillus, cladosporium, penicillum,) - suspension for injection - active: allergen extracts 100 pnu/ml (alternaria, aspergillus, cladosporium, penicillium) excipient: aluminium hydroxide phenol sodium chloride water for injection active: allergen extracts 1000 pnu/ml (alternaria, aspergillus, cladosporium, penicillum,) excipient: aluminium hydroxide phenol sodium chloride water for injection active: allergen extracts 10000 pnu/ml (alternaria, aspergillus, cladosporium, penicillum,) excipient: aluminium hydroxide phenol sodium chloride water for injection

European Union - English - EMA (European Medicines Agency)

merck sharp & dohme b.v. - caspofungin (as acetate) - candidiasis; aspergillosis - antimycotics for systemic use - treatment of invasive candidiasis in adult or paediatric patients;treatment of invasive aspergillosis in adult or paediatric patients who are refractory to or intolerant of amphotericin b, lipid formulations of amphotericin b and / or itraconazole. refractoriness is defined as progression of infection or failure to improve after a minimum of seven days of prior therapeutic doses of effective antifungal therapy;empirical therapy for presumed fungal infections (such as candida or aspergillus) in febrile, neutropaenic adult or paediatric patients.

European Union - English - EMA (European Medicines Agency)

accord healthcare s.l.u. - caspofungin acetate - candidiasis; aspergillosis - antimycotics for systemic use - treatment of invasive candidiasis in adult or paediatric patients.treatment of invasive aspergillosis in adult or paediatric patients who are refractory to or intolerant of amphotericin b, lipid formulations of amphotericin b and/or itraconazole. refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.empirical therapy for presumed fungal infections (such as candida or aspergillus) in febrile, neutropaenic adult or paediatric patients.

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

apvma permit - azoxystrobin(32g/kg)+metalaxyl-m(4g/kg)+fludioxonil(20g/kg) - group 4/11/12 fungicide

Canada - English - Health Canada

salus-haus - anise; coriander; spearmint; calamus; masterwort; absinthium; achillea millefolium l.; spearmint; calamus; glycyrrhiza glabra; bromelain; aspergillus oryzae; caraway; fennel - tablet - 30mg; 20mg; 30mg; 10mg; 10mg; 30mg; 30mg; 15mg; 15mg; 150mg; 8mg; 20mg; 20mg; 30mg - anise 30mg; coriander 20mg; spearmint 30mg; calamus 10mg; masterwort 10mg; absinthium 30mg; achillea millefolium l. 30mg; spearmint 15mg; calamus 15mg; glycyrrhiza glabra 150mg; bromelain 8mg; aspergillus oryzae 20mg; caraway 20mg; fennel 30mg - herbs and natural products

United States - English - NLM (National Library of Medicine)

alk-abello, inc. - solenopsis invicta (unii: 5o7cr4p444) (solenopsis invicta - unii:5o7cr4p444) - solenopsis invicta 0.05 g in 1 ml - hyposensitization (injection) therapy is a treatment for patients exhibiting allergic reactions to seasonal pollens, dust, molds, animal danders, various other inhalants, and in situations where the offending allergen cannot be avoided. prior to initiation of therapy, the clinical sensitivity should be established by careful evaluation of the patient’s history confirmed by diagnostic skin testing. hyposensitization should not be prescribed for sensitivities to allergens which can easily be avoided. a patient should not be immunized with preparations of allergens to which the patient has not demonstrated symptoms, ige antibodies, positive skin tests, or properly controlled challenge testing. in most cases, immunotherapy is not indicated for those allergens that can be eliminated or minimized by environmental control. patients on beta-blockers are not candidates for immunotherapy, as they can be non-responsive to beta-agonists that may be required to reverse a systemic reaction (also see warnings and adverse

United States - English - NLM (National Library of Medicine)

alk-abello, inc. - sarocladium strictum (unii: 3f36v0451w) (sarocladium strictum - unii:3f36v0451w) - sarocladium strictum 0.05 g in 1 ml - hyposensitization (injection) therapy is a treatment for patients exhibiting allergic reactions to seasonal pollens, dust, molds, animal danders, various other inhalants, and in situations where the offending allergen cannot be avoided. prior to initiation of therapy, the clinical sensitivity should be established by careful evaluation of the patient’s history confirmed by diagnostic skin testing. hyposensitization should not be prescribed for sensitivities to allergens which can easily be avoided. a patient should not be immunized with preparations of allergens to which the patient has not demonstrated symptoms, ige antibodies, positive skin tests, or properly controlled challenge testing. in most cases, immunotherapy is not indicated for those allergens that can be eliminated or minimized by environmental control. patients on beta-blockers are not candidates for immunotherapy, as they can be non-responsive to beta-agonists that may be required to reverse a systemic reaction (also see warnings and adverse